Cite
HARVARD Citation
Plimack, E. et al. (n.d.). Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet oncology. 18 (2), pp. 212-220. [Online].